Novo Nordisk AS (BSP:N1VO34) 5-Year EBITDA Growth Rate : 17.50% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Novo Nordisk AS 5-Year EBITDA Growth Rate?

Novo Nordisk AS's EBITDA per Share for the three months ended in Sep. 2024 was R$0.86.

During the past 12 months, Novo Nordisk AS's average EBITDA Per Share Growth Rate was 43.40% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 26.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 17.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Novo Nordisk AS was 166.20% per year. The lowest was -49.70% per year. And the median was 13.30% per year.

Competitive Comparison of Novo Nordisk AS's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's 5-Year EBITDA Growth Rate falls into.

Novo Nordisk AS 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Novo Nordisk AS (BSP:N1VO34) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Novo Nordisk AS 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (BSP:N1VO34) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines